We and others investigated a new approach to prion disease therapy based on the observation that 21% of mice heterozygous for the prion protein gene (prnp) and expressing approximately half the amount of PrPC survived terminal prion disease, and the remaining mice lived 2.5 times longer than prnp homozygous mice [64–66]. The gene discussed is PRNP; the disease is prion disease.